A compound according to formula I: wherein: R 1 denotes COOH, COOA, COA, CF 3, acyl, cyano, Het, tetrazolyl, sulfonyl, CON(R 3) 2 or CONHA; R 2 denotes H, Hal, A, O-A, Ar; R a denotes Ar, Het, O-Het, NH-Het, O-Ar, -O-(CH 2) m -Het, -NH-(CH 2) m -Het, NH-Ar, S 2 Ar, S Ar, -S-Ar, OCF 3; Y denotes CR f; X 1 and X 2 denote each independently of one another NR c or NR d; R b and R c together represent a chemical bond; R f and R e together represent a chemical bond; R d denotes H, A, -(CH 2) m -COOH; Q denotes the arylene Hal denotes F, Cl, Br or I; A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by Hal, OR 3, CN or N(R 3) 2 and wherein one or more, preferably 1 to 7 non-adjacent CH 2 -groups may be replaced by O, or S and/or by -CH=CH- or -C≡C- groups, or denotes cycloalkyl or cycloalkylalkylen having 3-7 ring C atoms; Ar denotes a monocyclic or bicyclic, saturated, unsaturated or aromatic carbocyclic ring having 6 to 14 carbon atoms which may be unsubstituted or substituted by a group selected from (R 4) n and/or (R 5) n; Het denotes a monocyclic or bicyclic, saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 N, O and/or S atoms which may be unsubstituted or substituted by a group selected from (R 4) n and/or (R 5) n; R 3 is H or alkyl; R 4 and R 5 are each independently selected from Hal, hydroxy, alkoxy, carboxy, carboxy-alkyl, perfluoro-alkyl, perfluoro-alkyloxy, acyl, alkylsulfonyl, sulfonyl, cyano, nitro, amino, amido, alkyl optionally substituted by a carboxy, or Het-alkyl optionally substituted by an acyl, alkylsulfonyl, -O(CH 2) n Ar, -O(CH 2) n Het, -(CH 2) m Het, OA, -NHCO(CH 2) m Ar, NHCO-(CH 2) m Het, CONHA, or alkyl; n denotes 0,1,2,3,4,5; and m denotes 0,1,2,3,4,5,6; and pharmaceutically acceptable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios. R 1 denotes COOH, COOA, COA, CF 3, acyl, cyano, Het, tetrazolyl, sulfonyl, CON(R 3) 2 or CONHA; R 2 denotes H, Hal, A, O-A, Ar; R a denotes Ar, Het, O-Het, NH-Het, O-Ar, -O-(CH 2) m -Het, -NH-(CH 2) m -Het, NH-Ar, S 2 Ar, S Ar, -S-Ar, OCF 3; Y denotes CR f; X 1 and X 2 denote each independently of one another NR c or NR d; R b and R c together represent a chemical bond; R f and R e together represent a chemical bond; R d denotes H, A, -(CH 2) m -COOH; Q denotes the arylene Hal denotes F, Cl, Br or I; A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by Hal, OR 3, CN or N(R 3) 2 and wherein one or more, preferably 1 to 7 non-adjacent CH 2 -groups may be replaced by O, or S and/or by -CH=CH- or -C≡C- groups, or denotes cycloalkyl or cycloalkylalkylen having 3-7 ring C atoms; Ar denotes a monocyclic or bicyclic, saturated, unsaturated or aromatic carbocyclic ring having 6 to 14 carbon atoms which may be unsubstituted or substituted by a group selected from (R 4) n and/or (R 5) n; Het denotes a monocyclic or bicyclic, saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 N, O and/or S atoms which may be unsubstituted or substituted by a group selected from (R 4) n and/or (R 5) n; R 3 is H or alkyl; R 4 and R 5 are each independently selected from Hal, hydroxy, alkoxy, carboxy, carboxy-alkyl, perfluoro-alkyl, perfluoro-alkyloxy, acyl, alkylsulfonyl, sulfonyl, cyano, nitro, amino, amido, alkyl optionally substituted by a carboxy, or Het-alkyl optionally substituted by an acyl, alkylsulfonyl, -O(CH 2) n Ar, -O(CH 2) n Het, -(CH 2) m Het, OA, -NHCO(CH 2) m Ar, NHCO-(CH 2) m Het, CONHA, or alkyl; n denotes 0,1,2,3,4,5; and m denotes 0,1,2,3,4,5,6; and pharmaceutically acceptable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.